Kestra Medical (KMTS) Q3 2026 Earnings Transcript

Kestra Medical reported Q3 revenue of $24.6M (+63% YoY) driven by >5,400 Assure prescriptions and raised FY2026 revenue guidance to $93M (+55% YoY). Gross margin expanded to 52.6% (up 900bps YoY; +200bps sequential), conversion rate ~46%, and cash was $291M as of Jan 31. Company secured Florida managed Medicaid contracts, added to the VA Federal Supply Schedule, received FDA approval for a new Assure algorithm, and entered an exclusive co-development/licensing deal with BioBeat including a $5M equity investment. GAAP net loss widened to $34.2M; adjusted EBITDA loss was $21.2M, while CapEx for the quarter was $9M supporting sales territory expansion to ~130 by fiscal year-end.

Analysis

Kestra’s recent operational moves—algorithm update + integration of continuous BP monitoring—create a compound structural advantage: fewer false alarms reduces non-therapeutic device returns and improves patient wear-time, while ABPM adds a diagnostic stickiness that raises the lifetime value of each prescription. Together these changes increase marginal revenue per fitted patient and steepen the firm’s unit-economics curve in a way incumbents that compete primarily on logistics will struggle to match without substantive product reinvestment.

Market-access wins (state Medicaid and federal GSA/FSS pathways) are low-friction addressable-demand expansions but will manifest unevenly: expect quarter-to-quarter step functions as contracts are onboarded and institutional procurement cycles run their 3–9 month course. Operational levers—RCM automation and conversion-rate gains—are the highest‑leverage near-term drivers of free cash flow because they convert booked prescriptions into billable, in-network dollars faster than incremental sales hires can grow top line.

Key asymmetries: catalysts cluster (conference rollout, peer-reviewed ACE PAS publication, fiscal-year planning cadence), creating identifiable binary events with outsized re-pricing potential. Primary risks are non-product: reimbursement shifts, adverse-event/legal noise, or a competitor securing exclusive payer/service deals; guideline-level expansion remains a multi-year process and is the largest single determinant of a sustained market growth re-rating.

Key Decisions for Investors

• Buy KMTS stock sized 1.5% of fund NAV, scale in over 4–8 weeks; target hold 18–24 months to capture algorithm rollout, VA/Florida ramp and potential guideline momentum. Hedge with a 9–12 month protective put sized to 50% of the equity position to cap downside from reimbursement or adverse-event shocks. Risk/reward: asymmetric upside if clinical/data catalysts validate adoption; downside limited via hedge to preserve optionality.
• Initiate a directional options trade: buy KMTS Jan 2027 LEAPS call spread (buy nearer-term ATM call, sell ~25% OTM call) sized at 0.5% NAV. Rationale: low-cost, capped-risk exposure to HRS rollout and ACE PAS publication with ~9–15 month horizon; maximum loss = premium paid, target 2–4x return if adoption accelerates.
• Event hedge / tactical trim: if KMTS gaps >20% on the HRS algorithm rollout or a major contract announcement, trim 40% of long exposure and deploy proceeds to buy 3–6 month out-of-the-money puts (insurance) or re-deploy into incremental long tranches on any pullback >12%. This realizes short-term profit while preserving optionality for multi-quarter commercial execution.